晚期非小细胞肺癌免疫治疗满两年停药的真实世界结局:I-STOP研究最终结果
I-STOP多中心观察性研究纳入173例接受单药PD-1/PD-L1抑制剂≥24个月的晚期NSCLC患者,28例(16.2%)在24个月停药。停药组与继续治疗组中位OS均未达到,无差异(HR 1.22,95%CI 0.50-2.95;p=0.66);停药组中位PFS为35.6个月,继续组未达到(HR 2.16,95%CI 1.04-4.48;p=0.035)。
要点
- 24个月停药未影响总生存,但无进展生存较继续治疗组缩短。
- PD-L1≤50%、脑转移、ECOG PS≥1或KRAS突变者停药后进展风险更高。
- 停药后再挑战客观缓解率62.5%,晚期3-4级免疫相关事件发生率3.5%。
核心结论
- 对持续疾病控制的晚期NSCLC患者,24个月停用免疫检查点抑制剂不损害生存结局,但部分亚组可能从继续治疗中获益。
研究设计与样本
- I-STOP为多中心观察性研究,纳入意大利12家机构中接受单药PD-1/PD-L1抑制剂≥24个月的晚期NSCLC患者,共173例可评估,中位随访55.4个月。
主要发现
- 24个月时停药28例(16.2%);停药组与继续组中位OS均未达到,无差异(HR 1.22,95%CI 0.50-2.95;p=0.66)。
- 停药组中位PFS为35.6个月,继续组未达到(HR 2.16,95%CI 1.04-4.48;p=0.035)。
- PD-L1≤50%、脑转移、ECOG PS≥1或KRAS突变患者停药后进展风险更高。
- 再挑战客观缓解率62.5%,晚期3-4级免疫相关事件发生率3.5%。
临床怎么用
- 对完成24个月免疫治疗且疾病控制的晚期NSCLC患者,可考虑停药,但需结合PD-L1表达、脑转移、ECOG PS和KRAS状态个体化决策。
局限性
- 停药组样本量较小(28例),为非随机观察性设计,需更大规模前瞻性研究确认可从延长治疗中获益的人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal duration of immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) remains undefined. While most trials adopt a 2-year treatment cap, evidence supporting this strategy in real-world practice is limited. The I-STOP study evaluated outcomes of patients with advanced NSCLC who achieved disease control after 24 months of ICI therapy and either discontinued or continued treatment. METHODS: I-STOP is a multicenter, observational study including patients with advanced NSCLC treated with single-agent PD-1/PD-L1 inhibitors for ≥ 24 months in 12 Italian institutions. Patients with complete response, partial response, or stable disease at 24 months were categorized according to treatment discontinuation. Progression-free survival (PFS) and overall survival (OS) were compared using 24-month landmark analyses; prognostic factors were assessed through Cox models. RESULTS: Among 173 eligible patients (median follow-up 55.4 months), 28 (16.2 %) discontinued ICI therapy at 24 months. Median OS was not reached in either cohort, with no difference between discontinuation and continuation groups (HR 1.22, 95 % CI 0.50-2.95; p = 0.66). Median PFS was 35.6 months in the discontinuation group versus not reached in the continuation group (HR 2.16, 95 % CI 1.04-4.48; p = 0.035). Higher progression risk after discontinuation was observed in patients with PD-L1 ≤ 50 %, brain metastases, ECOG PS ≥ 1, or KRAS mutations. Rechallenge achieved a 62.5 % response rate, and late grade 3-4 immune-related events were uncommon (3.5 %). CONCLUSIONS: Discontinuing ICIs at 24 months appears to be a safe strategy for patients with durable disease control, without compromising survival outcomes. Nonetheless, some subgroups may benefit from continued treatment. Larger prospective studies are needed to identify which patients could gain from prolonged immunotherapy.
引用
- Gemelli M, Sala L, Morabito A, et al. Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study. Eur J Cancer. 2026. PMID: 41734479. doi:10.1016/j.ejca.2026.116579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。